• FDA and EMA endorse the advancement of cobitolimod into phase III.

  • Our lead drug candidate cobitolimod has a new and unique mechanism of action to effectively and safely treat ulcerative colitis.

  • InDex Pharmaceuticals is developing treatments to increase the quality of life of patients suffering from immunological disorders.

Interim Report Q1 2020

InDex Pharmaceuticals Holding AB (publ) published its interim report for January-March 2020 on May 7 2020 at 08:00 a.m. CEST.